Is it Time to Dump Your Shares of Moderna?

Moderna's stock has declined approximately 80% over the past three years due to decreased demand for its COVID-19 vaccine, despite the approval of its RSV vaccine and progress in cost reduction. While the company aims for up to 10 product approvals, including multiple cancer vaccines, and anticipates significant operating cost reductions by 2027, investor focus remains on declining COVID-19 vaccine sales and uncertainty surrounding future vaccine policies. Despite these headwinds, analysts suggest long-term investors should maintain their positions, anticipating potential revenue growth as Moderna's pipeline progresses, particularly in oncology.

Analysis

Moderna (MRNA) has experienced a significant stock price decline of approximately 80% over the past three years, primarily driven by diminishing demand for its flagship COVID-19 vaccine, which generated peak annual revenue of $18.4 billion in 2022. Despite recent positive developments, including the approval of its RSV vaccine, advancements in updated coronavirus vaccines, and a strategic focus on cost reduction aiming for $1.4 billion to $1.7 billion in GAAP operating cost savings by 2027, investor sentiment remains subdued. Persistent concerns over falling COVID-19 vaccine sales, coupled with initially underwhelming RSV vaccine uptake and potential uncertainties stemming from future U.S. vaccine policies, such as changes to the HHS vaccine advisory panel, continue to exert pressure on the stock. However, Moderna possesses a robust late-stage pipeline with ambitions for up to ten new product approvals in the coming years, notably prioritizing oncology with seven cancer vaccine candidates in phase 2 or phase 3 trials. This pipeline, if even partially successful, represents a significant opportunity for diversified revenue streams and a potential turnaround in the company's financial trajectory, though the market has yet to fully price in this long-term potential.

Key Decisions for Investors

• Long-term investors should consider holding their positions, as the current share price may not fully reflect the potential future value derived from Moderna's extensive late-stage pipeline, particularly in the oncology sector.
• Closely monitor progress on key clinical trial milestones and upcoming product approvals, as these will be critical catalysts for re-evaluating the company's revenue diversification strategy and long-term growth prospects beyond its COVID-19 vaccine.
• Remain cognizant of ongoing headwinds, including competitive dynamics in the RSV market and potential shifts in public health policy related to vaccines, which could continue to impact near-term sentiment and stock performance.